| | | N | % |
|---|
| Age | [0–16] | 9 | 5.3 |
| [16–59] | 131 | 78.4 |
| [60-] | 27 | 16.1 |
| Sex | Female | 83 | 49,7 |
| Male | 84 | 50.2 |
| Ethnic group | Sub-Saharan Africans | 139 | 83,2 |
| Non sub-Saharan Africansa | 28 | 16.7 |
| Country of acquisition | Cameroon | 104 | 62.2 |
| Gabon | 27 | 16.1 |
| Congo-Brazzaville | 16 | 9.5 |
| Central African Republic | 6 | 3.5 |
| Othersb | 8 | 4.7 |
| Undetermined | 6 | 3.8 |
| Symptoms c,d | Itching | 74 | 44.3 |
| Calabar swelling | 54 | 32,3 |
| Subcutaneous oedema | 29 | 17.3 |
| Eyeworm | 39 | 23.3 |
| Other ocular symptoms | 24 | 14.3 |
| Subcutaneous worm migration | 8 | 4.7 |
| No symptom | 45 | 26.9 |
- aNon sub-Saharan African patients = Europeans (N = 26) and patients from North Africa (N = 2)
- bother countries: Benin, Ivory Coast, Equatorial Guinea, Mali, Rwanda, Democratic Republic of Congo
- ctotal percentage of different symptoms exceeds 100% as one patient may have presented several symptoms simultaneously
- dmain data from the 3 patients who reported non-endemic countries as countries of contamination (see discussion): Ivory Coast: VFR, itching, microfilaremia: 3/mL; Mali (South): VFR, stay of 3 months, itching, microfilaremia: 4/mL; Rwanda: VFR, subcutaneous oedema (ankle), serology + with specific arc at immunoelectrophoresis
